Dermata Therapeutics, Inc. DRMA
We take great care to ensure that the data presented and summarized in this overview for Dermata Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DRMA
View allLatest Institutional Activity in DRMA
Top Purchases
Top Sells
About DRMA
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Insider Transactions at DRMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 06
2022
|
Andrew Seth Sandler |
BUY
Grant, award, or other acquisition
|
Direct |
10,120
+29.5%
|
-
|
|
Oct 06
2022
|
David F Hale |
BUY
Grant, award, or other acquisition
|
Direct |
30,155
+28.48%
|
-
|
|
Oct 06
2022
|
Mary Fisher |
BUY
Grant, award, or other acquisition
|
Direct |
9,810
+29.5%
|
-
|
|
Oct 06
2022
|
Kathleen D. Scott |
BUY
Grant, award, or other acquisition
|
Direct |
11,359
+29.5%
|
-
|
|
Oct 06
2022
|
Wendell Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
20,654
+24.87%
|
-
|
|
Oct 06
2022
|
Brittany Bradrick |
BUY
Grant, award, or other acquisition
|
Direct |
9,810
+29.5%
|
-
|
|
Jul 07
2022
|
Andrew Seth Sandler |
BUY
Grant, award, or other acquisition
|
Direct |
8,874
+38.69%
|
-
|
|
Jul 07
2022
|
David F Hale |
BUY
Grant, award, or other acquisition
|
Direct |
26,441
+36.72%
|
-
|
|
Jul 07
2022
|
Kathleen D. Scott |
BUY
Grant, award, or other acquisition
|
Direct |
9,960
+38.69%
|
-
|
|
Jul 07
2022
|
Wendell Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
18,110
+30.26%
|
-
|
|
Jul 07
2022
|
Mary Fisher |
BUY
Grant, award, or other acquisition
|
Direct |
8,602
+38.69%
|
-
|
|
Jul 07
2022
|
Brittany Bradrick |
BUY
Grant, award, or other acquisition
|
Direct |
8,602
+38.69%
|
-
|
|
Apr 07
2022
|
David F Hale |
BUY
Grant, award, or other acquisition
|
Direct |
15,466
+44.71%
|
-
|
|
Apr 07
2022
|
Brittany Bradrick |
BUY
Grant, award, or other acquisition
|
Direct |
5,031
+50.0%
|
-
|
|
Apr 07
2022
|
Andrew Seth Sandler |
BUY
Grant, award, or other acquisition
|
Direct |
5,190
+50.0%
|
-
|
|
Apr 07
2022
|
Kathleen D. Scott |
BUY
Grant, award, or other acquisition
|
Direct |
5,826
+50.0%
|
-
|
|
Apr 07
2022
|
Mary Fisher |
BUY
Grant, award, or other acquisition
|
Direct |
5,031
+50.0%
|
-
|
|
Apr 07
2022
|
Wendell Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
10,593
+40.64%
|
-
|
|
Nov 23
2021
|
Gerald T Proehl President, CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
20,000
+25.15%
|
$40,000
$2.4 P/Share
|
|
Aug 17
2021
|
Christopher J. Nardo Senior VP, CDO |
BUY
Conversion of derivative security
|
Indirect |
2,439
+50.0%
|
-
|